Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 10 Mar 2023
Today's top stories include: Nine-year cap to complete MBBS, elective-based credits offered in NMC letter Students enrolled in...
Read Full NewsA trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.
A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.
Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care
1.
Alecensa (alectinib) Offers Hope for Certain Patients With ALK Positive NSCLC
2.
PFS in R/R Mantle Cell Lymphoma is Improved by Ibrutinib-Venetoclax.
3.
Products for Intimate Care and Cancer; Boost for Colorectal Cancer Stool Tests; Ultrasonic Biopsy?
4.
Childhood brain tumors develop early in highly specialized nerve cells, research reveals
5.
Oncologist Sued for Double-Billing; Pharmacy Deserts; 'She Loved Scotch and Pizza'
1.
How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology
2.
Uncovering the Subtle Signs of Prostate Cancer: Early Detection is Key
3.
Unlocking the Potential of Lutathera: A Revolutionary Cancer Treatment
4.
Understanding Macrocytosis: Causes, Symptoms, and Treatment Options
5.
AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge